Figure 1.

Trial schema. (A) Twenty-one patients with bilateral GGOs received Sintilimab (200mg i.v., Q3W) for up to 10 cycles at six weeks or later after surgical resection. During the use of Sintilimab, the radiological evaluation was performed at every three cycles within treatment period and every three months during follow-up. A total of seven cases preferred the second resection to remove the remaining resectable GGOs after 6–8 cycles of immunotherapy. (B) For these cases underwent twice resections, IHC staining, mIF, WES, and WGBS were performed on resected GGOs to investigate molecular features and discover neo-biomarkers. GGO, ground glass opacity; CT, computed tomography; WES, whole exome sequencing; WGBS, whole genome bisulfite sequencing; mIF, multiplex immunofluorescence; PCA, principal component analysis.